Hearscape
Therapies database

Find a therapy. Follow the evidence.

See what is being studies, who is developing it, and how far it has progressed.

Search therapy records

Search a therapy, company, target, indication, or trial ID. Narrow by approach, stage, or status, then open a record to check its sources.

More filters and sort (1 active)
4 results
CIL001 (Paliroden) by Cilcare
Cilcare SAS · Small Molecule · Phase 1/2
ActiveTherapeuticStronger sources
Population
Adults · 45–75 years
Type 2 diabetes with speech-in-noise difficulty
Evidence
trial
Confidence
92%
Indications
Hearing LossSensorineural Hearing LossHidden Hearing LossCochlear Synaptopathy
Details
NS101 by Neuracle Science
Neuracle Science Co., Ltd. · Biologic · Phase 1/2
ActiveTherapeuticStronger sources
Population
Adults · 19–70 years
Steroid-treated persistent unilateral SSNHL
Evidence
trial
Confidence
92%
Indications
Hearing LossSensorineural Hearing LossSudden Sensorineural Hearing LossCochlear Synaptopathy
Details
OTO-413 by Otonomy
Otonomy · Biologic · Phase 2
DiscontinuedTherapeutic
Population
Adults · 21–64 years
Speech-in-noise hearing impairment
Evidence
company
Confidence
95%
Indications
Hearing LossSensorineural Hearing LossHidden Hearing LossCochlear Synaptopathy
Details
PIPE-505 by Pipeline Therapeutics
Contineum Therapeutics · Small Molecule · Phase 1/2
CompletedTherapeutic
Population
Adults · 18–75 years
Bilateral SNHL with speech-in-noise deficits
Evidence
trial
Confidence
86%
Indications
Hearing LossSensorineural Hearing LossHidden Hearing LossCochlear Synaptopathy
Details

A listing is not proof of safety or effectiveness. Approval and availability may vary by indication and country.

How records are checked